Stephen C Farrell
CIK 1188757 · President & CEO · last filed 2025-03-06
"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.
Charts
Trading activity, where the exposure sits, and each trade against the stock price.
PSTA price and trades
Daily close with each Form 4 filing on this company marked: green = open-market buy, red = open-market sale, purple = grants, exercises, gifts and other non-market transactions. Marker size scales with the dollar value.
Shares held
Shares owned after each reported transaction on this company (direct holdings as reported).
Open-market buying and selling
by monthDollar value of open-market purchases (code P, up) and sales (code S, down) across all companies, by filing month. Grants, exercises and gifts are excluded.
Exposure by company
latestMost recently reported shares × current price. Faded bars (*) have had no filing in 3 years, so the person may no longer hold them. Click a bar to chart that company.
Filer Profile
SUITE 360
WAKEFIELD, MA 01880
Holdings By Company
| Symbol | Role | Shares | Price | Disclosed Exposure | Lifetime OM Net | Filings | Latest Filed |
|---|---|---|---|---|---|---|---|
| STAA | President & CEO | 35,156 | $25.13 | $883.5K | $0 | 20 | 2025-03-06 |
| Convey Health Solutions Holdings, Inc. (CNVY) Delisted | CHIEF EXECUTIVE OFFICER | 636,862 | $10.51 | $6.69M | $585.0K | 2 | 2022-03-30 |
| LCTX | Director | — | $0.83 | — | $0 | 1 | 2020-07-02 |
| Lineage Cell Therapeutics, Inc. (BTX.WS) Delisted | Director | 97,450 | — | — | $350.4K | 10 | 2018-07-03 |
| QUESTCOR PHARMACEUTICALS INC (QCOR) Delisted | Director | 15,433 | — | — | -$2.57M | 11 | 2014-03-11 |
| Stream Global Services, Inc. (OOO.WS) Delisted | Executive Vice President & CFO | 3,640 | — | — | $9.1K | 4 | 2008-12-18 |
| QUESTCOR PHARMACEUTICALS INC (QSC) Delisted | Director | — | — | — | $0 | 3 | 2008-01-03 |
| POLYMEDICA CORP (PSTA) Delisted | President | 0 | — | — | -$3.14M | 6 | 2007-11-13 |
Recent Filings · Page 3 of 6
60 filings| Filed | Symbol | Action | Net Shares | Net $ | Link |
|---|---|---|---|---|---|
| 2018-06-18 | STAA | Grant (A) | +3,691 | $0 | EDGAR |
| 2018-03-19 | STAA | Grant (A) | — | $0 | EDGAR |
| 2017-07-05 | Lineage Cell Therapeutics, Inc. (BTX.WS) Delisted | Grant (A) | — | $0 | EDGAR |
| 2017-06-15 | STAA | Grant (A) | — | $0 | EDGAR |
| 2016-08-10 | STAA | Grant (A) | — | $0 | EDGAR |
| 2016-07-05 | Lineage Cell Therapeutics, Inc. (BTX.WS) Delisted | Grant (A) | — | $0 | EDGAR |
| 2016-06-27 | STAA | Grant (A) | — | $0 | EDGAR |
| 2016-01-05 | STAA | Grant (A) | — | $0 | EDGAR |
| 2015-11-10 | Lineage Cell Therapeutics, Inc. (BTX.WS) Delisted | Buy (P) | +50,000 | $191.5K | EDGAR |
| 2015-07-06 | Lineage Cell Therapeutics, Inc. (BTX.WS) Delisted | Grant (A) | — | $0 | EDGAR |
10b5-1: the filer ticked the box for trades made under a Rule 10b5-1 trading plan, which sets the sales (or buys) in advance, so they say less about the insider's view at the time than a discretionary trade. The plan's adoption date is shown when the filing's footnotes give it.
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment, and an amended or cancelled notice is not listed. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes. Someone who is no longer an officer or director (or never was) files no Form 4, so for them a sale shows up only on a later notice, which lists the seller's sales from the 3 months before it. "No sale on file" means neither record shows one; a dash in Net $ means the value filed on the notice doesn't fit the stock's price (likely a typo).